

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma

Authors

Evgenii Shumilov,^{1*} Rebecca Wurm-Kuczera,^{2*} Joseph Kauer,³ Meng Wang,² Paolo Mazzeo,^{4,5} Hristo Boyadzhiev,^{6,7} Niklas Gebauer,⁸ Udo Holtick,⁹ Alexander Hölscher,¹⁰ Marcel Teichert,¹¹ Paulina Maria Nierychlewska,¹² Christoph Kimmich,¹³ Philipp Berning,¹ Thomas Melchardt,¹⁴ Vanja Zeremski,¹⁵ Chiara Wirths,¹⁶ Philipp Nakov,¹⁷ Christian Schultze-Florey,¹⁸ Giuliano Filippini Velazquez,¹⁹ Vadim Lesan,²⁰ Isabelle Krämer,³ Florian Kaiser,²¹ Ursula Vehling-Kaiser,²¹ Anna Ossami-Saidy,²² Henriette Huber,²³ Akhil Behringer,¹ Martin Bentz,²³ Julia Katharina Scholz,²⁴ Philipp Gödel,⁹ Ulf Schnetzke,²⁵ Vladan Vucinic,²⁶ Elisabeth Shorb,²⁷ Susanne Ghandili,²⁸ Andrea Kerkhoff,¹ Sebastian Scheich,²⁹ Semra Aydin,³⁰ Karin Mayer,³⁰ Ulrike Bacher,³¹ Kai Wille,³² Bertram Glass,²² Thomas Oellerich,²⁹ Francis Ayuk,³³ Florian Heidel,¹⁷ Lorenz Thurner,²⁰ Mathias Lutz,¹⁹ Mathias Hänel,³⁴ Christian W. Scholz,³⁵ Mareike Tometten,¹⁶ Christiane Pott,¹⁷ Peter Dreger,⁵ Dimitrios Mougiakakos,¹⁵ Sascha Dietrich,¹⁰ Enrico Derenzini,¹² Björn Chapuy,^{2,36} Bastian von Tresckow,¹¹ Thomas Pabst,⁶ Fabian Müller²⁴ and Georg Lenz¹

¹Department of Medicine A, Hematology, Oncology and

Pneumology, University Hospital Muenster, Muenster, Germany;

²Department of Hematology, Oncology, and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; ³Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; ⁴Department of Hematology and Medical

Oncology, University Hospital Goettingen, Goettingen, Germany; ⁵Department of Hematology and Medical Oncology, INDIGHO Laboratory, University Medical Center Goettingen (UMG), Goettingen, Germany; ⁶Department of Medical Oncology, University

Hospital Bern, University of Bern, Bern, Switzerland; ⁷Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerland; ⁸Department for

Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany; ⁹Department I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany; ¹⁰Department of

Hematology, Oncology and Immunology, University Hospital of Duesseldorf, Duesseldorf, Germany; ¹¹Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University

Hospital Essen, University of Duisburg-Essen, Essen, Germany; ¹²Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy; ¹³Department of Hematology and Oncology,

University Hospital Oldenburg, Oldenburg, Germany; ¹⁴IIIrd Medical Department at the Paracelsus Medical University Salzburg, Cancer Center, Salzburg; Salzburg Cancer Research Institute, Salzburg;

Austrian Group for Medical Tumor Therapy (AGMT), Salzburg; Cancer Cluster, Salzburg, Austria; ¹⁵University Hospital Magdeburg, Department of Hematology, Oncology, and Cell

Therapy, Magdeburg, Germany; ¹⁶Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany; ¹⁷Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany; ¹⁸Department of Hematology, Hemostasis, Oncology and

Stem Cell Transplantation, Hannover Medical School, Hannover, Germany; ¹⁹Department of Hematology, University Hospital Augsburg, Augsburg, Germany; ²⁰Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg, Germany; ²¹MVZ Dr. Vehling-Kaiser GmbH, Landshut, Germany; ²²Department of

Hematology and Cell Therapy, Helios Klinikum Berlin-Buch, Berlin, Germany; ²³Department of Internal Medicine III, Hospital of Karlsruhe, Karlsruhe, Germany; ²⁴Department of Internal Medicine 5 - Hematology and Oncology, University Hospital of Erlangen, Erlangen, Germany; ²⁵Department of Internal Medicine II, Hematology and Medical Oncology, University Hospital Jena, Jena, Germany; ²⁶Department of Hematology, Cell Therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany;

²⁷Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; ²⁸Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²⁹Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany; ³⁰Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany; ³¹Department of Hematology, University Hospital Inselspital and University of Bern, Bern, Switzerland; ³²University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany;

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

University Hospital Oldenburg, Oldenburg, Germany; ¹⁴IIIrd Medical Department at the Paracelsus Medical University Salzburg, Cancer Center, Salzburg; Salzburg Cancer Research Institute, Salzburg;

Austrian Group for Medical Tumor Therapy (AGMT), Salzburg; Cancer Cluster, Salzburg, Austria; ¹⁵University Hospital Magdeburg, Department of Hematology, Oncology, and Cell

Therapy, Magdeburg, Germany; ¹⁶Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany; ¹⁷Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany; ¹⁸Department of Hematology, Hemostasis, Oncology and

Stem Cell Transplantation, Hannover Medical School, Hannover, Germany; ¹⁹Department of Hematology, University Hospital Augsburg, Augsburg, Germany; ²⁰Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg, Germany; ²¹MVZ Dr. Vehling-Kaiser GmbH, Landshut, Germany; ²²Department of

Hematology and Cell Therapy, Helios Klinikum Berlin-Buch, Berlin, Germany; ²³Department of Internal Medicine III, Hospital of Karlsruhe, Karlsruhe, Germany; ²⁴Department of Internal Medicine 5 - Hematology and Oncology, University Hospital of Erlangen, Erlangen, Germany; ²⁵Department of Internal Medicine II, Hematology and Medical Oncology, University Hospital Jena, Jena, Germany; ²⁶Department of Hematology, Cell Therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany;

²⁷Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; ²⁸Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²⁹Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany; ³⁰Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany; ³¹Department of Hematology, University Hospital Inselspital and University of Bern, Bern, Switzerland; ³²University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany;

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

³³Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³⁴Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany; ³⁵Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany and ³⁶German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany

**EShu and RW-K contributed equally as first authors.*

LETTER TO THE EDITOR

Correspondence:

G. LENZ - georg.lenz@ukmuenster.de

<https://doi.org/10.3324/haematol.2025.300063>

Received: October 17, 2025.

Accepted: March 26, 2026.

Early view: April 2, 2026.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

**Outcomes of real-world complete responders after fixed-duration glofitamab in
relapsed/refractory large B-cell lymphoma**

Supplemental Table S1. Efficacy and outcomes of glofitamab therapy in CR patients with r/r LBCL.

Parameters	n (%)
Patients	52 (100)
Median days to BORR, range	136 (17-360)
Immunoglobulin replacement therapy	21 (40.4)
Documented CR type	
Metabolic	33 (63.5)
Radiologic	19 (36.5)
Relapse/PD rate following initiation of Glo	8 (15.4)
Median time to relapse/PD following first Glo administration, mo, range	11 (IQR 10; 7-17)
Reason for EOT with Glo	52 (100)
- completion of 12 cycles glofitamab and no any subsequent consolidation	36 (69.2)
- treatment toxicity	5 (9.6)
- secondary malignancy	1 (1.9)
- CAR-T consolidation	3 (5.8)
- Allo-HSCT consolidation after maximum of 5 cycles glofitamab	4 (7.7)
- Allo-HSCT consolidation after 12 cycles glofitamab	1 (1.9)
Relapse under glofitamab	2 (9.6)
Ongoing therapy	0
Median FU from Glo initiation, mo, range	19 (IQR 15; 29-14)
Remission state at last FU	
CR	47 (90.4)
r/r disease	5 (9.6)
Status at last FU	
Alive	39 (75)
Dead	13 (25)
Cause of death, n = 10	
r/r lymphoma	4 (7.7)
non-lymphoma reasons	9 (17.3)
- Infection	5 (9.6)
- unknown	2 (3.8)
- bleeding	1 (1.9)
- secondary malignancy	1 (1.9)

Percentages refer to total number of events scored. Glo, glofitamab; CR, complete response; r/r, relapsed/refractory; LBCL, large B-cell lymphoma; PD, progressive disease; mo, months; EOT, end of treatment; CAR-T, chimeric antigen receptor T-cell therapy; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; FU, follow-up. * one patient underwent allo-HSCT consolidation following regular EOT after 12 cycles of glofitamab

Supplemental Table S2. Efficacy of CAR-T cell therapies and of bispecific antibodies applied in combination with other agents in relapsed/refractory LBCL patients.

Study name; investigated product	Prior therapies	Patient population (n)	ORR	CRR	PFS	OS	Reference
ZUMA-1 Axicabtagene ciloleucel	≥2, including DLBCL patients who failed HDCT/ASCT	n=111 (n=101 treated with axi-cel), median 3 prior lines of therapy	83%	58%	2-year PFS 39%; mPFS 5.9 mo.	2-year OS 50.5%; mOS 25.8 mo.	1,2
ZUMA-7 Axicabtagene ciloleucel vs. second line HDCT/ASCT	1, only primary refractory or relapse ≤12 months, eligible for HDCT/ASCT	n=180 (in the axi-cel arm) and n=179 (in the SOC arm), 1 prior line of therapy	83% vs. 50%	65% vs. 32%	2-year PFS 46% vs. 27%; mPFS 14.7 vs. 3.7 mo.	2-year OS 60% vs. 51% (*crossover in SOC); mOS not reached vs. 31.1 mo (*crossover in SOC)	3,4
TRANSCEND NHL001 Lisocabtagene maraleucel	≥2, including those who failed HDCT/ASCT	n=270, median 3 prior lines of therapy	73%	53%	2-year PFS 40.6%; mPFS 6.8 mo.	2-year OS 50.5%; mOS 27.3 mo.	5
TRANSFORM Lisocabtagene maraleucel vs. second line HDCT/ASCT	1, only primary refractory or relapse ≤12 months, eligible for HDCT/ASCT	n=92 (in the liso-cel arm) and n=92 (in the SOC arm), 1 prior line of therapy	87% vs. 49%	74% vs. 43%	3-year PFS 50.9% vs. 26.5%; Not reached vs. 6.2 mo.	3-year OS 62.8% vs. 51.8% (**crossover in SOC); mOS not reached for both (**crossover in SOC)	6,7
STARGLO Glofitamab - GemOx vs. R-GemOx	≥1, HDCT/ASCT ineligible	n=183 (in the glofitamab - GemOx arm)	68.3% vs. 40.7%	58.5% vs. 25.3%	2-year PFS not available;	2-year OS 52.8% vs. 33.5%; mOS	8,9

		and n=91 (in the R-GemOx arm), median 1 prior line of therapy			mPFS 13.8 vs. 3.6 mo.	25.5 vs. 12.9 mo.	
EPCORE NHL-2 Epcoritamab - GemOx	≥1, HDCT/ASCT ineligible	n=103, median 2 prior lines of therapy	85%	61%	mPFS 11.2 mo.	mOS 21.6 mo.	10
Phase 1b/2 Mosunetuzumab + polatuzumab vedotin	≥1, HDCT/ASCT ineligible	n=120, median 2 prior lines of therapy	59.2%	45.9%	mPFS 11.4 mo.	mOS 23.3 mo.	11
SUNMO Phase 3 Trial Mosunetuzumab + polatuzumab vedotin vs. R-GemOx	≥1, HDCT/ASCT ineligible	n=138 (in the mosunetuzumab - pola arm) and n=70 (in the R-GemOx arm), median 2 prior line of therapy	70.3% vs. 40%	51.4% vs. 24.3%	1-year PFS 48.5% vs. 17.8%; mPFS 11.5 vs. 3.8 mo.	1-year PFS 48.5% vs. 17.8%; mPFS 11.5 vs. 3.8 mo.	12
Phase 1 Trial BP41072 Englumafusp alfa (CD19-4-1BBL) combined with glofitamab in patients with r/r B-cell lymphoma	≥1, HDCT/ASCT ineligible	n=83 with aggressive lymphoma, median 3 prior lines of therapy	67.5%	56.6%	mPFS 9.7 mo.	mOS 20.9 mo.	13
LOTIS-7, arm E Loncastuximab tesirine combined with glofitamab in patients with aggressive B-cell lymphoma	≥1, CAR-T and HDCT/ASCT eligible	n=30 with aggressive lymphoma	93.3%	86.7%	mPFS not reached	mOS not reached	14
Glofitamab, NP30179 Phase I/II Trial Glofitamab monotherapy	≥2, including patients who failed HDCT/ASCT and/or CAR-T cell therapy	N=154, median 3 prior lines of therapy	52%	39%	1-year PFS 37%; mPFS 4.9 mo.	1-year OS 50%; mOS 12 mo.	15,16


Epcoritamab, EPCORE™ NHL-1 trial Epcoritamab monotherapy	≥2, including patients who failed HDCT/ASCT and/or CAR-T cell therapy	N=157, median 3 prior lines of therapy	63.1%	40.1%	2-year PFS 27.8%; mPFS 4.4 mo.	2-year OS 44.6%; mOS 18.5 mo.	17,18
---	---	--	-------	-------	-----------------------------------	----------------------------------	-------

CAR-T, chimeric antigen receptor T-cells; r/r, relapsed/refractory; LBCL, large B-cell lymphoma; ORR, overall response rate; CRR, complete response rate; PFS, progression-free survival; mPFS, median progression-free survival; OS, overall survival; mOS, median overall survival; HDCT/ASCT, high-dose chemotherapy/autologous stem cell transplantation; mo, months; SOC, standard of care; mo, months; GemOx, gemcitabine, oxaliplatin; R-GemOx, rituximab, gemcitabine, oxaliplatin; pts., patients; FU, follow-up; Pola, polatuzumab vedotin

*57% of HDCT/ASCT patients in ZUMA-7 received CAR-T cells in third-line;

**66% of HDCT/ASCT patients in TRANSFORM crossed over to receive lisocabtagene maraleucel in third-line.

Supplemental Figure S1. CONSORT diagram summarizing screening and inclusion of 52 patients achieving CR after monotherapy with glofitamab at 25 European centers (treatment Aug 2021–Feb 2025).



R/r LBCL, relapsed/refractory large B-cell lymphoma; CR, complete remission; CAR-T, chimeric antigen receptor T-cell therapy; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; *one patient underwent allo-HSCT after completion of 12 cycles glofitamab.

References (Table S2):

1. Locke FL, Ghobadi A, Jacobson CA, et al: Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol* 20:31-42, 2019
2. Neelapu SS, Jacobson CA, Ghobadi A, et al: Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. *Blood* 141:2307-2315, 2023
3. Westin JR, Oluwole OO, Kersten MJ, et al: Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. *N Engl J Med* 389:148-157, 2023
4. Locke FL, Miklos DB, Jacobson CA, et al: Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. *N Engl J Med* 386:640-654, 2021
5. Abramson JS, Palomba ML, Gordon LI, et al: Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. *Blood* 143:404-416, 2024
6. Abramson JS, Solomon SR, Arnason J, et al: Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. *Blood* 141:1675-1684, 2023
7. Kamdar MK, Solomon SR, Arnason J, et al: Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell

- lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. *J Clin Oncol* 42:7013-7013, 2024
8. Abramson JS, Ku M, Hertzberg M, et al: Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. *Lancet* 404:1940-1954, 2024
 9. Abramson JS, Ku M, Hertzberg M, et al: Glofitamab plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of starglo. *Hematol Oncol* 43:e76_70093, 2025
 10. Brody JD, Jørgensen J, Belada D, et al: Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. *Blood* 145:1621-1631, 2025
 11. Budde LE, Olszewski AJ, Assouline S, et al: Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. *Nat Med* 30:229-239, 2024
 12. Westin J, Zhang H, Kim W, et al: Mosunetuzumab plus Polatuzumab Vedotin is superior to R-GemOx in transplant-ineligible patients with r/r LBCL: primary results of the phase iii sunmo trial. *Hematol Oncol* 43:eLBA3_70110, 2025
 13. Hutchings M, Dickinson MJ, Gritti G, et al: Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072. *Blood* 144:990-990, 2024
 14. Alderuccio JP, Okada C, Crochet G, et al: Initial results from LOTIS-7: a phase 1b study of Loncastuximab tesirine plus Glofitamab in patients with relapsed/refractory (r/r) diffuse large b-cell lymphoma (DLBCL). *Hematol Oncol* 43:e78_70093, 2025
 15. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al: Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med* 387:2220-2231, 2022
 16. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al: Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study. *Blood* 144:865-865, 2024
 17. Thieblemont C, Karimi YH, Ghesquieres H, et al: Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. *Leukemia* 38:2653-2662, 2024
 18. Thieblemont C, Phillips T, Ghesquieres H, et al: Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. *J Clin Oncol* 41:2238-2247, 2023